{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-004421","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.655060+00:00","generated_at":"2026-05-19T10:37:48.324520+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Phio Pharmaceuticals appoints Lisa Carson as CFO/PAO; Infarinato shifts to VP Strategic Development","bullets":["Lisa Carson named VP Finance and Administration and designated principal financial and accounting officer, effective June 6, 2025.","Robert Infarinato ceased as PFO/PAO, appointed VP Strategic Development effective June 9 to focus on INTASYL portfolio business development.","Carson's compensation: $290k base salary, up to 30% annual bonus, $25k sign-on stipend; at-will employment.","Company announces strategic initiative to raise awareness of INTASYL siRNA portfolio (~30 compounds); positive interim Phase 1b results for PH-762 in skin cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-004421","json":"https://secwatch.observer/filing/0001683168-25-004421.json","markdown":"https://secwatch.observer/filing/0001683168-25-004421.md","text":"https://secwatch.observer/filing/0001683168-25-004421.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825004421/0001683168-25-004421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825004421/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T10:37:48.324520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42260cb819","claim":"Robert Infarinato was appointed as VP, Strategic Development at Phio Pharmaceuticals Corp..","evidence_excerpt":"Also effective June 6, 2025, Mr. Infarinato, who was previously the Company’s Chief Financial Officer, now serves as VP, Strategic Development of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825004421/0001683168-25-004421-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"VP, Strategic Development"}],"fact_type":"executive_change"},{"claim_id":"65259bd977","claim":"Lisa Carson was appointed as VP, Finance and Administration at Phio Pharmaceuticals Corp..","evidence_excerpt":"designated Lisa Carson, VP, Finance and Administration of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of June 6, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825004421/0001683168-25-004421-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"designated"},{"label":"Role","value":"VP, Finance and Administration"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}